Form 4: Maravai Lifesciences Executive Chairman Acquires 175,000 Shares

Carl Hull, Executive Chairman of Maravai Lifesciences, purchased 175,000 shares of Class A Common Stock at an average price of $5.64.

Summary

• Carl Hull, the Executive Chairman of Maravai Lifesciences, acquired 175,000 shares of Class A Common Stock on November 11, 2024.
• The shares were purchased at a weighted average price of $5.64, with individual transaction prices ranging from $5.52 to $5.73.
• The purchase was made indirectly through The Hull Living Trust.
• Following the transaction, Mr. Hull beneficially owns 175,000 shares indirectly through The Hull Living Trust, 35,000 shares indirectly through Glossatori, LLC, and 267,072 shares directly.

Sentiment

Score: 6

Explanation: The document reflects a routine insider transaction. While the purchase may be seen as a positive sign, it's not a major event that would significantly alter the sentiment.

Positives

• The purchase by the Executive Chairman may signal confidence in the company's future prospects.
• The acquisition increases the Executive Chairman's stake in the company.

Industry Context

This is a routine filing related to insider trading activity and is common for publicly traded companies. It does not indicate any specific trend in the broader industry.

Comparison to Industry Standards

• Insider trading activity is a common occurrence in publicly traded companies, and this transaction is within the normal range of such activities.
• Similar filings are regularly made by executives at comparable companies such as Thermo Fisher Scientific (TMO) and Danaher Corporation (DHR).

Stakeholder Impact

• The purchase may be viewed positively by shareholders as it indicates confidence from a key executive.

Key Dates

Keywords

Maravai Lifesciences, MRVI, Carl Hull, Executive Chairman, stock purchase, insider trading, Class A Common Stock, beneficial ownership